Research Article
Efficacy of Neoadjuvant Targeted Therapy in Treatment of Patients with Localised Clear-Cell Renal Cell Carcinoma
Table 1
Baseline patients characteristics, tumour stage and size, kidney function, and concomitant pathology, n = 118.
| | Indicator | Statistical units | Main group, n = 58 (%) | Control group, n = 60 (%) | Statistical evaluation |
| | Age, years | M ± SD (95% CI) | 55.3 ± 10.3 (52.6–58) | 54.5 ± 12 (51.4–57.6) | Mann–Whitney U test; | | Sex | Male, n (%) | 39 (67.2) | 34 (56.7) | x2 = 1.39
| | Female, n (%) | 19 (32.7) | 26 (43.3) | | T | 1a, n (%) | 7 (12.1) | 5 (8.3) | x2 = 7.3; | | 1b, n (%) | 3 5 (60.3) | 31 (51.7) | | 2a, n (%) | 1 2 (20.7) | 22 (36.7) | | 2b, n (%) | 4 (6.9) | 2 (3.3) |
| | ECOG | Me [25%; 75%] | 1 [0, 1] | 1 [0, 1] | Mann–Whitney U test; | | Body mass index | Me [25%; 75%] | 28.6 [25.3; 33.2] | 28, 4 [26.9; 30.4] | Mann–Whitney U test; | | Haemoglobin | Me [25%; 75%] | 130, 5 [115; 141] | 135 [118; 149] | Mann–Whitney U test; | | Kidney tumour size, mm | M ± SD (95% CI) | 60.7 ± 19.8 (55.5–66) | 62.5 ± 16.7 (58.2–66.9) | Mann–Whitney U test; | | Total glomerular | M ± SD (95% CI) | 88.6 ± 26.1(76.7–100.5) | 90.5 ± 22.5 (80.5–100.5) | Mann–Whitney U test; | | Blood creatinine (μmol/L) | M ± SD (95% CI) | 94.5 ± 2 (89.3–99.7) | 90 ± 2.4 (83.7–96.5) | Mann–Whitney U test; | | CKD | n (%) | 4 (6, 9) | 3 (5) | x2 = 0.19; | | Concomitant pathology | n (%) | 29 (50) | 28 (46.7) | x2 = 0.13; |
|
|
SD, standard deviation; CKD, chronic kidney disease; ECOG, East Cooperation Oncology Group status.
|
